NeoStem today announced that the company has been ranked #1 regionally in the New York Tri-State region and #7 nationally on Deloitte’s 2012 Technology Fast 500. The ranking is a list of the 500 fastest growing technology, media, telecommunications, life sciences, and clean technology companies in North America.
Based in New York, NeoStem is focused on developing cell therapy products, technologies, and procedures. Through its subsidiary Progenitor Cell Therapy, the company is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. NeoStem’s most clinically advanced therapeutic product candidate, AMR-001, is being developed at Amorcyte, LLC, which was acquired by the company in 2011.
NeoStem’s business strategy combines a contract development and manufacturing organization (CDMO) with a medically important cell therapy product development program providing for near- and long-term revenue growth opportunities. The products developed this way are focused on markets for medical products centered around industries such as cardiovascular disease, autoimmune disorders, and regenerative medicine.
Dr. Robin L. Smith, NeoStem’s chairman and CEO, said, “We are proud to be recognized for this achievement as we build NeoStem into a top tier biopharmaceutical company and thrilled to be honored alongside such fast-growing, successful companies such as Celgene, LinkedIn, and Google. On behalf of the entire NeoStem team, I would like to thank Deloitte & Touche, LLP for their recognition of our efforts.”
For more information on NeoStem, visit www.neostem.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
